INTERPACE BIOSCIENCES, INC. (IDXG) Financial Statements (2024 and earlier)

Company Profile

Business Address WATERVIEW PLAZA, SUITE 310
PARSIPPANY, NJ 07054
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,4985,0325,0795,5964,8286,309
Cash and cash equivalents3,4985,0325,0795,5964,8286,309
Receivables4,9834,8305,5294,7155,0324,792
Inventory, net of allowances, customer advances and progress billings1,2271,0931,1771,1741,2241,246
Inventory1,2271,0931,1771,1741,2241,246
Disposal group, including discontinued operation      28
Other current assets1,8411,5762,3672,1732,2941,610
Other undisclosed current assets(1,227)(1,093)(1,177)(1,174)(1,224)(1,246)
Total current assets:10,32211,43812,97512,48412,15412,739
Noncurrent Assets
Operating lease, right-of-use asset1,8641,9782,0902,2982,439867
Property, plant and equipment790762606506480428
Intangible assets, net (including goodwill)  272265448611,179
Intangible assets, net (excluding goodwill)  272265448611,179
Other noncurrent assets454545454580
Total noncurrent assets:2,6992,8122,9673,3933,8252,554
TOTAL ASSETS:13,02114,25015,94215,87715,97915,293
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,71411,46611,20710,79310,92513,083
Employee-related liabilities1,631
Accounts payable1,5441,3521,6891,5821,0501,446
Accrued liabilities10,17010,1149,5189,2119,87510,006
Debt5,100 1,500542578668
Disposal group, including discontinued operation660858858858858858
Other undisclosed current liabilities    1,6581,922201
Total current liabilities:17,47412,32413,56513,85114,28314,810
Noncurrent Liabilities
Long-term debt and lease obligation, including:4,24311,56511,3071,7481,848184
Long-term debt, excluding current maturities4,24311,56511,30711,13211,1659,988
Other undisclosed long-term debt and lease obligation    (9,384)(9,317)(9,988)
Liabilities, other than long-term debt6,4406,5056,7406,8967,0675,368
Other liabilities4,9684,9494,8634,7804,7014,736
Operating lease, liability1,4721,5561,6461,7481,848184
Business combination, contingent consideration, liability   231368518632
Other undisclosed noncurrent liabilities    9,3849,3179,988
Total noncurrent liabilities:10,68318,07018,04718,02818,23215,540
Total liabilities:28,15730,39431,61231,87932,51530,350
Temporary equity, carrying amount46,53646,53646,53646,53646,53646,536
Equity
Equity, attributable to parent(61,672)(62,680)(62,206)(62,538)(63,072)(61,593)
Common stock405405405405405404
Treasury stock, value(2,008)(1,997)(1,985)(1,985)(1,976)(1,934)
Additional paid in capital188,146188,017187,865187,708187,516187,390
Accumulated deficit(248,215)(249,105)(248,491)(248,666)(249,017)(247,453)
Total equity:(61,672)(62,680)(62,206)(62,538)(63,072)(61,593)
TOTAL LIABILITIES AND EQUITY:13,02114,25015,94215,87715,97915,293

Income Statement (P&L) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Revenues10,2839,07811,0269,826(17,828)8,189
Cost of revenue(4,147)(4,124)(4,191)(3,848)(3,321)(3,457)
Other undisclosed gross profit     26,160 
Gross profit:6,1364,9546,8355,9785,0114,732
Operating expenses(4,823)(4,970)(6,003)(5,303)(4,957)(5,512)
Operating income (loss):1,313(16)83267554(780)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(259)(252)(174)19(1,191)(217)
Other undisclosed loss from continuing operations before equity method investments, income taxes (896)     
Income (loss) from continuing operations before equity method investments, income taxes:158(268)658694(1,137)(997)
Other undisclosed income (loss) from continuing operations before income taxes662(256)(259)(260)(265)(268)
Income (loss) from continuing operations before income taxes:820(524)399434(1,402)(1,265)
Income tax expense (benefit)(5)(4)(4)(4)(5)11
Income (loss) from continuing operations:815(528)395430(1,407)(1,254)
Loss before gain (loss) on sale of properties:(14,208)
Income (loss) from discontinued operations75(86)(220)(79)(157)(12,954)
Net income (loss) available to common stockholders, diluted:890(614)175351(1,564)(14,208)

Comprehensive Income ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net income (loss):890(614)175351(1,564)(14,208)
Comprehensive income (loss), net of tax, attributable to parent:890(614)175351(1,564)(14,208)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: